KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Neogenomics (NEO) over the last 16 years, with Q4 2025 value amounting to $159.2 million.

  • Neogenomics' Receivables - Net rose 578.05% to $159.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $159.2 million, marking a year-over-year increase of 578.05%. This contributed to the annual value of $159.2 million for FY2025, which is 578.05% up from last year.
  • As of Q4 2025, Neogenomics' Receivables - Net stood at $159.2 million, which was up 578.05% from $155.3 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Receivables - Net registered a high of $159.2 million during Q4 2025, and its lowest value of $102.9 million during Q1 2021.
  • For the 5-year period, Neogenomics' Receivables - Net averaged around $129.8 million, with its median value being $128.3 million (2023).
  • Data for Neogenomics' Receivables - Net shows a peak YoY increase of 2109.93% (in 2021) and a maximum YoY decrease of 122.18% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Neogenomics' Receivables - Net stood at $112.1 million in 2021, then grew by 6.76% to $119.7 million in 2022, then rose by 9.62% to $131.2 million in 2023, then grew by 14.72% to $150.5 million in 2024, then rose by 5.78% to $159.2 million in 2025.
  • Its last three reported values are $159.2 million in Q4 2025, $155.3 million for Q3 2025, and $153.1 million during Q2 2025.